Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

por Ou, Sai-Hong Ignatius
Publicado 2011

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

por Ou, Sai-Hong Ignatius, Nagasaka, Misako
Publicado 2020

ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?

por Nagasaka, Misako, Ou, Sai-hong Ignatius
Publicado 2022

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

por Zhang, Shannon S, Ou, Sai-Hong Ignatius
Publicado 2022

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

por Zhang, Shannon S., Ou, Sai-Hong Ignatius
Publicado 2022

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKI...

por Zhang, Shannon S, Ou, Sai-hong Ignatius
Publicado 2022

Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?

por Ou, Sai-Hong Ignatius, Soo, Ross A
Publicado 2015

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

por Ou, Sai-Hong Ignatius, Zhu, Viola W.
Publicado 2020

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

por Brazel, Danielle, Kim, Jennifer, Ou, Sai-Hong Ignatius
Publicado 2023

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

por Brazel, Danielle, Ou, Sai-Hong Ignatius, Nagasaka, Misako
Publicado 2023

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020

por Ou, Sai-Hong Ignatius, Zhu, Viola W., Nagasaka, Misako
Publicado 2020

In Response to Dr. Steven Sorscher

por Zhang, Shannon S., Schrock, Alexa B., Nagasaka, Misako, Ou, Sai-Hong Ignatius
Publicado 2022

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer

por Anwar, Kaleem, Nguyen, Lee, Nagasaka, Misako, Ou, Sai-Hong Ignatius, Chan, Alexandre
Publicado 2022

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large‐scale multinational trials (PROFILE 1005 and 1007)

por Ou, Sai‐Hong Ignatius, Tang, Yiyun, Polli, Anna, Wilner, Keith D., Schnell, Patrick
Publicado 2016

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

por Zhu, Viola W, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius
Publicado 2019

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

por Ou, Sai-Hong Ignatius, Nagasaka, Misako, Brazel, Danielle, Hou, Yujie, Zhu, Viola W.
Publicado 2021

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States

por Lin, Huamao M., Yin, Yu, Crossland, Victoria, Wu, Yanyu, Ou, Sai-Hong Ignatius
Publicado 2022

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET...

por Ou, Sai-Hong Ignatius, Soo, Ross A., Kubo, Akihito, Kawaguchi, Tomoya, Ahn, Myung-Ju
Publicado 2014

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

por Xia, Bing, Nagasaka, Misako, Zhu, Viola W., Ou, Sai-Hong Ignatius, Soo, Ross A.
Publicado 2020

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature

por Klempner, Samuel J, Mehta, Pareen, Schrock, Alexa B, Ali, Siraj M, Ou, Sai-Hong Ignatius
Publicado 2017